Richard McKinnon Walsh

Dr. Richard McKinnon Walsh

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
RWRichard McKinnon Walsh
Richard McKinnon Walsh
JAJoseph Ambrose
Joseph Ambrose
JJJarrid L Jack
Jarrid L Jack
AEAustin E Eades
Austin E Eades
BBBailey A Bye
Bailey A Bye
MVMichael VanSaun
Michael VanSaun
Background: CXCR1/2 inhibitors are being implemented with immunotherapies in PDAC clinical trials. CXC-ligands are a family of cytokines responsible for stimulating these receptors; while typically secreted by activated immune cells, fibroblasts, and even adipocytes, they are also secreted by immune-evasive cancer cells. CXC-ligand release is known to occur in response to inflammatory stimuli. Adipose tissue is an endocrine organ and a source of inflammatory signaling peptides. Importantly, adipose-derived cytokines and chemokines are implicated as potential drivers of tumor cell immune evasion; cumulatively, these findings suggest that targeting CXC-ligands may be beneficial in the context of obesity. Methods: RNA-sequencing of human PDAC cell lines was used to assess influences of adipose conditioned media on the cancer cell transcriptome. The adipose-induced secretome of PDAC cells was validated with ELISA for induction of CXCL5 secretion. Human tissue data from CPTAC was used to correlate IL-1β and TNF expression with both CXCL5 mRNA and protein levels. CRISPR-Cas9 was used to knockout CXCL5 from a murine PDAC KPC cell line to assess orthotopic tumor studies in syngeneic, diet-induced obese mice. Flow cytometry and immunohistochemistry were used to compare the immune profiles between tumors with or without CXCL5. Mice-bearing CXCL5 competent or deficient tumors were monitored for differential tumor size in response to anti-PD-1 immune checkpoint blockade therapy. Results: Human adipose tissue conditioned media stimulates CXCL5 secretion from PDAC cells via either IL-1β or TNF; neutralization of both is required to significantly block the release of CXCL5 from tumor cells. Ablation of CXCL5 from tumors promoted an enriched immune phenotype with an unanticipatedly increased number of exhausted CD8 T cells. Application of anti-PD-1 treatment to control tumors failed to alter tumor growth, yet treatment of CXCL5-deficient tumors showed response by significantly diminished tumor mass. Conclusions: In summary, our findings show that both TNF and IL-1β can stimulate CXCL5 release from PDAC cells in vitro, which correlates with expression in patient data. CXCL5 depletion in vivo alone is sufficient to promote T cell infiltration into tumors, increasing efficacy and requiring checkpoint blockade inhibition to alleviate tumor burden.

29 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
BBBailey Bye
Bailey Bye
JJJarrid Jack
Jarrid Jack
APAlexandra Pierce
Alexandra Pierce
RWRichard McKinnon Walsh
Richard McKinnon Walsh
AEAustin E. Eades
Austin E. Eades
MVMichael VanSaun
Michael VanSaun
Background: Oncogenic KRAS mutations are nearly ubiquitous in pancreatic ductal adenocarcinoma (PDAC), yet therapeutic attempts to target KRAS, as well as downstream MAPK pathway effectors, have shown limited clinical success. While KRAS canonically drives MAPK signaling via RAF-MEK-ERK, it is also known to play a role in PI3K-AKT signaling. Methods: Our therapeutic study targeted the PI3K pathway with the drug Omipalisib (p110α/β/δ/γ and mTORC1/2 inhibitor) in combination with two different MAPK pathway inhibitors: Trametinib (MEK1/2 inhibitor) or SHP099-HCL (SHP099; SHP2 inhibitor). Western blot analysis demonstrated that the application of Trametinib or SHP099 alone selectively blocked ERK phosphorylation (pERK) but failed to suppress phosphorylated AKT (pAKT). Conversely, Omipalisib alone successfully inhibited pAKT but failed to suppress pERK. Therefore, we hypothesized that a combination therapeutic comprised of Omipalisib with either Trametinib or SHP099 would inhibit two prominent mitogenic pathways, MAPK and PI3K-AKT, and effectively suppress PDAC growth. Results: In vitro studies demonstrated that, in several cell lines, both Omipalisib/Trametinib and Omipalisib/SHP099 combination therapeutic strategies were more effective than treatment with each drug individually at reducing proliferation, colony formation, and cell migration compared to vehicle controls. In vivo oral administration of combined Omipalisib/Trametinib treatment was significantly more effective than Omipalisib/SHP099 in reducing implanted tumor growth, and the Omipalisib/Trametinib treatment more effectively reduced tumor progression and prolonged survival in an aggressive genetically engineered mouse model of PDAC than either Omipalisib or Trametinib alone. Conclusions: Altogether, our data support a rationale for a dual treatment strategy targeting both PI3K and MAPK pathways in pancreatic cancers.

28 August 2026
Verified
Other
Open access
KSKaty L. Swancutt
Katy L. Swancutt
RWRichard McKinnon Walsh
Richard McKinnon Walsh
SQSydney Quijano
Sydney Quijano
ESEmily Schueddig
Emily Schueddig
DKDevin C Koestler
Devin C Koestler
DWDanny R. Welch
Danny R. Welch
Top ten most abundant sequences aligning to mt-TR in each sample normalized to total mapped reads (in reads per million, RPM). Notable low overall abundance of sequences from pre-treated small RNA extracted from female mouse liver reflects technical challenges in the state of the art of RNA sequencing of tRNA and tRF (n = 3 samples per WT or MNX strain).

28 August 2026
Verified
Other
Open access
KSKaty L. Swancutt
Katy L. Swancutt
RWRichard McKinnon Walsh
Richard McKinnon Walsh
SQSydney Quijano
Sydney Quijano
ESEmily Schueddig
Emily Schueddig
DKDevin C Koestler
Devin C Koestler
DWDanny R. Welch
Danny R. Welch
AlphaFold3 predictive modeling of D-T Loop interactions of mt-TR

28 August 2026
Verified
Other
Open access
KSKaty L. Swancutt
Katy L. Swancutt
RWRichard McKinnon Walsh
Richard McKinnon Walsh
SQSydney Quijano
Sydney Quijano
ESEmily Schueddig
Emily Schueddig
DKDevin C Koestler
Devin C Koestler
DWDanny R. Welch
Danny R. Welch
AlphaFold3 predictive modeling of mt-TR suggests different stability and D–T-loop structures among strains. A, Sequences for each mt-TR (from left to right: C, H, and F) modeled without posttranscriptional modifications (PTM) and displayed predicted instability/low confidence. Predicted template modeling “pTM” scores range from 0.26 to 0.28 on a scale of 0–1. B, Three rows of images are displayed with increased zoom from top to bottom. To improve confidence predictions and better reflect known principles of tRNA folding (37), sequences for each strain were modeled according to reported PTM of human mt-TR (m1A, m2G, and Ψ; ref. 31). PTM inclusion increased predicted stability and confidence scoring compared with that of unmodified sequences (pTM range, 0.75–0.77 vs. 0.26–0.28). The D–T-loop interactions have the lowest scoring confidence, which aligns with the commonly observed transcript end (Table 1) of fragments between C: U53/G54; H: U55/G56; F: U54/G55 (highlighted in green in the bottom two rows of images). Nucleotides and structure of predicted interactions between the D–T-loop differ across strains: T-loop G54 is predicted to interact with the D-loop in C mt-TR; T-loop U57 is predicted to interact with the D-loop in H mt-TR; both U54/G55 are predicted to interact specifically with A17 of the T-loop in C mt-TR. Specific predictive bonding and distances between the center of nucleotides are listed in tRF patterns in liver tissue. pIDDT, predicted local distance difference test.

29 July 2026 in Quarterly Reviews of Biophysics
Verified
Journal Article
Open access
DWDanny R. Welch
Danny R. Welch
KSKaty L. Swancutt
Katy L. Swancutt
RWRichard McKinnon Walsh
Richard McKinnon Walsh
GFGabrielle L. Fisette
Gabrielle L. Fisette
This review summarizes evidence related to metastasis-associated genes and their functions. Their discovery, rigor of evidence for involvement in cancer metastasis, correlations and anticorrelations with metastatic propensity, biochemical function(s), and clinical associations are summarized and critically evaluated. What emerges is a picture whereby function is determined by context (tumor type, which in vivo or in vitro assays were used to assess function(s), whether RNA or protein is being measured, and redundancy of related molecules, cellular location, protein stability, etc.) due to differential regulation and interactions. Many metastasis genes have been implicated in individual steps of the metastatic cascade, while others impact multiple steps, complicating the ability to ascribe definitive mechanism(s) of action. Likewise, many metastasis-regulatory molecules are involved in multiple cellular signaling pathways due to interactions with other macromolecules. The implications of the complexity of metastasis genetics and epigenetics for prognosis and treatment are also briefly discussed.